6 days Ago By ABMN Staff
Geode Capital Management LLC boosted its holdings in Ligand Pharmaceuticals Incorporated ( NASDAQ:LGND – Free Report ) by 2.4% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 438,441 shares of the biotechnology company’s stock after purchasing an additional 10,171 shares during the quarter.
Geode Capital Management LLC’s holdings in Ligand Pharmaceuticals were worth $46,989,000 at the end of the most recent reporting period. A number of other institutional investors have also recently bought and sold shares of LGND. Vanguard Group Inc.
raised its position in shares of Ligand Pharmaceuticals by 5.8% in the fourth quarter. Vanguard Group Inc.
now owns 2,085,627 shares of the biotechnology company’s stock valued at $223,475,000 after buying an additional 115,005 shares in the last quarter. Franklin Resources Inc. increased its stake in Ligand Pharmaceuticals by 95.
9% during the 4th quarter. Franklin Resources Inc. now owns 185,402 shares of the biotechnology company’s stock worth $19,866,000 after acquiring an additional 90,743 shares during the period.
Norges Bank acquired a new position in Ligand Pharmaceuticals in the 4th quarter valued at $4,960,000. Fisher Asset Management LLC lifted its position in shares of Ligand Pharmaceuticals by 68.9% during the 4th quarter.
Fisher Asset Management LLC now owns 100,638 shares of the biotechnology company’s stock valued at $10,783,000 after acquiring an additional 41,064 shares during the period. Finally, Loomis Sayles & Co. L P grew its holdings in shares of Ligand Pharmaceuticals by 6.
7% during the 4th quarter. Loomis Sayles & Co. L P now owns 397,700 shares of the biotechnology company’s stock worth $42,614,000 after purchasing an additional 24,921 shares in the last quarter.
Institutional investors own 91.28% of the company’s stock. Wall Street Analysts Forecast Growth Several equities research analysts recently weighed in on the stock.
Benchmark reaffirmed a “buy” rating and set a $135.00 price objective on shares of Ligand Pharmaceuticals in a research report on Monday, December 23rd. StockNews.
com upgraded shares of Ligand Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday. Barclays boosted their price objective on shares of Ligand Pharmaceuticals from $150.00 to $160.
00 and gave the company an “overweight” rating in a research report on Monday, December 16th. Finally, Stifel Nicolaus started coverage on Ligand Pharmaceuticals in a report on Thursday, April 10th. They issued a “buy” rating and a $143.
00 target price on the stock. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.
com, Ligand Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $146.43. Insider Activity In related news, CFO Octavio Espinoza sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 4th.
The shares were sold at an average price of $115.03, for a total value of $575,150.00.
Following the completion of the transaction, the chief financial officer now owns 18,879 shares in the company, valued at $2,171,651.37. This trade represents a 20.
94 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink . Insiders own 5.
90% of the company’s stock. Ligand Pharmaceuticals Stock Up 2.2 % NASDAQ LGND opened at $106.
59 on Tuesday. The company has a market cap of $2.05 billion, a price-to-earnings ratio of 42.
47 and a beta of 1.07. Ligand Pharmaceuticals Incorporated has a twelve month low of $67.
72 and a twelve month high of $129.90. The business’s fifty day moving average is $110.
59 and its 200 day moving average is $112.13. Ligand Pharmaceuticals Profile ( Free Report ) Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide.
Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. Featured Stories Want to see what other hedge funds are holding LGND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ligand Pharmaceuticals Incorporated ( NASDAQ:LGND – Free Report ).
Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter ..
